Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Early results for novel hemophilia A infusion

Chowdary P et al. ASH 2018, Abstract 489

Publish date:: January 9, 2019

Key clinical point: A novel human factor VIII variant, given as a single infusion, shows promise for the treatment of severe hemophilia A.

Major finding: A single infusion of the factor VIII variant resulted in activity levels of about 6%, compared with 1% or less at baseline.

Study details: The findings were from the first four patients in a phase 1/2 dose-escalation study.

Disclosures: Dr. Chowdary reported financial relationships with Bayer, CSL Behring, Baxalta, Baxter, Biogen, Freeline, Novo Nordisk, Pfizer, Roche, Shire, and SOBI.

Read the article here.

Citation:

Chowdary P et al. ASH 2018, Abstract 489.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Bleeding Disorders

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

Hemochromatosis variants may confer 10-fold higher risk of liver cancer,

Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction,

Mouth splints decrease risk of post–dental extraction bleeding in hemophilia,

Low VWF levels or blood group O not linked to intracerebral hemorrhage risk,